Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors α antagonists.

Ammazzalorso A, Carrieri A, Verginelli F, Bruno I, Carbonara G, D'Angelo A, De Filippis B, Fantacuzzi M, Florio R, Fracchiolla G, Giampietro L, Giancristofaro A, Maccallini C, Cama A, Amoroso R.

Eur J Med Chem. 2016 May 23;114:191-200. doi: 10.1016/j.ejmech.2016.02.064. Epub 2016 Feb 27.

PMID:
26974385
2.

Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.

Ammazzalorso A, De Filippis B, Giampietro L, Amoroso R.

ChemMedChem. 2013 Oct;8(10):1609-16. doi: 10.1002/cmdc.201300250. Epub 2013 Aug 12. Review.

PMID:
23939910
3.

Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARα.

Ammazzalorso A, D'Angelo A, Giancristofaro A, De Filippis B, Di Matteo M, Fantacuzzi M, Giampietro L, Linciano P, Maccallini C, Amoroso R.

Eur J Med Chem. 2012 Dec;58:317-22. doi: 10.1016/j.ejmech.2012.10.019. Epub 2012 Oct 23.

PMID:
23137448
4.

Resveratrol and its metabolites bind to PPARs.

Calleri E, Pochetti G, Dossou KSS, Laghezza A, Montanari R, Capelli D, Prada E, Loiodice F, Massolini G, Bernier M, Moaddel R.

Chembiochem. 2014 May 26;15(8):1154-1160. doi: 10.1002/cbic.201300754. Epub 2014 May 5.

5.

Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines.

Ammazzalorso A, De Lellis L, Florio R, Bruno I, De Filippis B, Fantacuzzi M, Giampietro L, Maccallini C, Perconti S, Verginelli F, Cama A, Amoroso R.

Chem Biol Drug Des. 2017 Nov;90(5):1029-1035. doi: 10.1111/cbdd.13026. Epub 2017 Jul 19.

PMID:
28544586
6.

Peroxisome proliferator-activated receptor transactivational effects in HepG2 cells of cembranoids from the soft coral Lobophytum crassum Von Marenzeller.

Thao NP, Luyen BT, Ngan NT, Dat le D, Cuong NX, Nam NH, Kiem PV, Song SB, Minh CV, Kim YH.

Arch Pharm Res. 2015;38(5):769-75. doi: 10.1007/s12272-014-0382-9. Epub 2014 Apr 2.

PMID:
24691831
7.

Phytoceramide and sphingoid bases derived from brewer's yeast Saccharomyces pastorianus activate peroxisome proliferator-activated receptors.

Murakami I, Wakasa Y, Yamashita S, Kurihara T, Zama K, Kobayashi N, Mizutani Y, Mitsutake S, Shigyo T, Igarashi Y.

Lipids Health Dis. 2011 Aug 24;10:150. doi: 10.1186/1476-511X-10-150.

8.
9.

Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists.

Ammazzalorso A, Giancristofaro A, D'Angelo A, Filippis BD, Fantacuzzi M, Giampietro L, Maccallini C, Amoroso R.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4869-72. doi: 10.1016/j.bmcl.2011.06.028.

PMID:
21742490
10.

Computational and biological evaluation of N-octadecyl-N'-propylsulfamide, a selective PPARα agonist structurally related to N-acylethanolamines.

Moreno-Santos I, Pavón FJ, Romero-Cuevas M, Serrano A, Cano C, Suardíaz M, Decara J, Suarez J, de Fonseca FR, Macías-González M.

PLoS One. 2014 Mar 20;9(3):e92195. doi: 10.1371/journal.pone.0092195. eCollection 2014.

11.

Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters.

Bility MT, Thompson JT, McKee RH, David RM, Butala JH, Vanden Heuvel JP, Peters JM.

Toxicol Sci. 2004 Nov;82(1):170-82. Epub 2004 Aug 13.

PMID:
15310864
12.

Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.

Carrieri A, Giudici M, Parente M, De Rosas M, Piemontese L, Fracchiolla G, Laghezza A, Tortorella P, Carbonara G, Lavecchia A, Gilardi F, Crestani M, Loiodice F.

Eur J Med Chem. 2013 May;63:321-32. doi: 10.1016/j.ejmech.2013.02.015. Epub 2013 Feb 24.

PMID:
23502212
14.

Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids.

Bionaz M, Baumrucker CR, Shirk E, Vanden Heuvel JP, Block E, Varga GA.

J Dairy Sci. 2008 Jul;91(7):2808-13. doi: 10.3168/jds.2007-0789. Erratum in: J Dairy Sci. 2009 Sep;92(9):4715. Dosage error in article text.

15.

The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.

Mansour M.

Prog Mol Biol Transl Sci. 2014;121:217-66. doi: 10.1016/B978-0-12-800101-1.00007-7. Review.

PMID:
24373239
16.

Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus.

Sheldrick EL, Derecka K, Marshall E, Chin EC, Hodges L, Wathes DC, Abayasekara DR, Flint AP.

Biochem J. 2007 Aug 15;406(1):175-83.

17.

Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.

Brown JD, Plutzky J.

Circulation. 2007 Jan 30;115(4):518-33. Review.

PMID:
17261671
18.
19.

Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist.

Bajare S, Anthony J, Nair A, Marita R, Damre A, Patel D, Rao C, Sivaramakrishnan H, Deka N.

Eur J Med Chem. 2012 Dec;58:355-60. doi: 10.1016/j.ejmech.2012.10.027. Epub 2012 Oct 25.

PMID:
23142675
20.

The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists.

De Lellis L, Cimini A, Veschi S, Benedetti E, Amoroso R, Cama A, Ammazzalorso A.

ChemMedChem. 2018 Feb 6;13(3):209-219. doi: 10.1002/cmdc.201700703. Epub 2018 Jan 10. Review.

PMID:
29276815

Supplemental Content

Support Center